But the AACR is being touted because that will be when the full phase 1 data set should be presented. Although as you say the only important bit for the share price and investors should be when then full data results are RNSd.
Are you investigating genetic typing (e.g. using AI) to determine which cancers are likely to be best treated with pre|CISION drugs and which side effects are likely for which patients?
We have designed a very data rich Phase 1 study that will measure a number of exploratory biomarkers. These data will be presented in 2024 when new intellectual property has been protected.